2023
Top advances of the year: Head and neck cancer
Verma A, Burtness B. Top advances of the year: Head and neck cancer. Cancer 2023, 129: 1308-1312. PMID: 36692372, DOI: 10.1002/cncr.34654.Peer-Reviewed Original ResearchConceptsProgression-free survivalFavorable-risk patientsRisk patientsNeck cancerHuman papillomavirus-associated oropharyngeal cancerGemcitabine/cisplatin chemotherapyImmature survival dataVirus-related cancersIntermediate-risk patientsFirst-line treatmentPhase 3 trialCooperative group trialsTreatment deintensificationMetastatic headOverall survivalPostoperative therapySmoking historyOropharyngeal cancerAntibody nivolumabCisplatin chemotherapyTransoral resectionTransoral surgeryNasopharyngeal cancerGroup trialsGy radiation
2022
Trilynx: A Phase 3 Trial of Xevinapant and Concurrent Chemoradiotherapy (CRT) for Locally Advanced Head and Neck Cancer
Schoenfeld J, Cohen E, Nutting C, Licitra L, Burtness B, Omar M, Bouisset F, Nauwelaerts H, Urfer Y, Zanna C, Bourhis J. Trilynx: A Phase 3 Trial of Xevinapant and Concurrent Chemoradiotherapy (CRT) for Locally Advanced Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2022, 112: e20-e21. DOI: 10.1016/j.ijrobp.2021.12.046.Peer-Reviewed Original ResearchProgression-free survivalConcurrent CRTConcurrent chemoradiotherapyEvent-free survivalOverall survivalEFS eventsLA-SCCHNAdvanced squamous cell carcinomaRandomized phase 2 studyDefinitive concurrent chemoradiotherapyECOG PS 0T cell-dependent pathwayLocoregional control rateObjective response ratePhase 2 studyPhase 3 trialPlatinum-based chemotherapyHealth-related qualitySquamous cell carcinomaStandard concurrent chemoradiotherapyBiomarkers of responseStandard of careThree-year followIntensity-modulated radiotherapyExposure-response relationship
2021
TrilynX: A phase 3 trial of xevinapant and concurrent chemoradiation for locally advanced head and neck cancer.
Bourhis J, Burtness B, Licitra L, Nutting C, Schoenfeld J, Sarkouh R, Bouisset F, Nauwelaerts H, Urfer Y, Zanna C, Cohen E. TrilynX: A phase 3 trial of xevinapant and concurrent chemoradiation for locally advanced head and neck cancer. Journal Of Clinical Oncology 2021, 39: tps6091-tps6091. DOI: 10.1200/jco.2021.39.15_suppl.tps6091.Peer-Reviewed Original ResearchEvent-free survivalEFS eventsConcurrent chemoradiationAdvanced squamous cell carcinomaRandomized phase 2 studyECOG PS 0T cell-dependent pathwayLocoregional control ratePhase 2 studyPhase 3 trialPlatinum-based chemotherapySquamous cell carcinomaBiomarkers of responseStandard of careThree-year followIntensity-modulated radiotherapyExposure-response relationship× ULNBackbone therapyDefinitive chemoradiationEligible patientsLA-SCCHNMonotherapy periodX ULNConcurrent chemoradiotherapy
2017
373TiP KEYNOTE-412: Phase 3 trial of pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
Yen C, Machiels J, Licitra L, Rischin D, Waldron J, Burtness B, Gregoire V, Tao Y, Yorio J, Aksoy S, Ikeda S, Hong R, Ge J, Brown H, Bidadi B, Siu L. 373TiP KEYNOTE-412: Phase 3 trial of pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Annals Of Oncology 2017, 28: x110. DOI: 10.1093/annonc/mdx665.036.Peer-Reviewed Original Research
2015
342TiP Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048
Yen C, Klochikhin A, Cohen E, Vermorken J, Harrington K, Tahara M, Ge J, Geib J, Jin F, Burtness B. 342TiP Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048. Annals Of Oncology 2015, 26: ix93. DOI: 10.1093/annonc/mdv527.29.Peer-Reviewed Original Research11TiP Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048
Klochikhin A, Greil R, Cohen E, Vermorken J, Harrington K, Tahara M, Ge J, Geib J, Jin F, Burtness B. 11TiP Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048. Annals Of Oncology 2015, 26: viii5. DOI: 10.1093/annonc/mdv514.01.Peer-Reviewed Original Research